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Abstract
Ovarian carcinoma (OC) is the most lethal gynecological malignancy. Despite the advances
in the treatment of OC with combinatorial regimens, including surgery and platinum-based
chemotherapy, patients generally exhibit poor prognosis due to high chemotherapy resis-
tance. Herein, we tested the hypothesis that DNA damage response (DDR) pathways are
involved in resistance of OC patients to platinum chemotherapy. Selected DDR signals
were evaluated in two human ovarian carcinoma cell lines, one sensitive (A2780) and one
resistant (A2780/C30) to platinum treatment as well as in peripheral blood mononuclear
cells (PBMCs) from OC patients, sensitive (n = 7) or resistant (n = 4) to subsequent chemo-
therapy. PBMCs from healthy volunteers (n = 9) were studied in parallel. DNA damage was
evaluated by immunofluorescence γH2AX staining and comet assay. Higher levels of intrin-
sic DNA damage were found in A2780 than in A2780/C30 cells. Moreover, the intrinsic DNA
damage levels were significantly higher in OC patients relative to healthy volunteers, as
well as in platinum-sensitive patients relative to platinum-resistant ones (all P<0.05). Fol-
lowing carboplatin treatment, A2780 cells showed lower DNA repair efficiency than A2780/
C30 cells. Also, following carboplatin treatment of PBMCs ex vivo, the DNA repair efficiency
was significantly higher in healthy volunteers than in platinum-resistant patients and lowest
in platinum-sensitive ones (t1/2 for loss of γH2AX foci: 2.7±0.5h, 8.8±1.9h and 15.4±3.2h, re-
spectively; using comet assay, t1/2 of platinum-induced damage repair: 4.8±1.4h, 12.9±1.9h
and 21.4±2.6h, respectively; all P<0.03). Additionally, the carboplatin-induced apoptosis
rate was higher in A2780 than in A2780/C30 cells. In PBMCs, apoptosis rates were inverse-
ly correlated with DNA repair efficiencies of these cells, being significantly higher in plati-
num-sensitive than in platinum-resistant patients and lowest in healthy volunteers (all
P<0.05). We conclude that perturbations of DNA repair pathways as measured in PBMCs
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from OC patients correlate with the drug sensitivity of these cells and reflect the individual-
ized response to platinum-based chemotherapy.
Introduction
Ovarian cancer (OC) is the fifth most common type of cancer in females and the leading cause
of mortality for gynecological malignancies, with epithelial carcinoma being the most frequent
variety [1,2]. OC is typically diagnosed in advanced stages and often carries a dismal prognosis,
even though current treatment strategies including aggressive surgical cytoreduction and plati-
num-paclitaxel chemotherapy seem to have significantly improved the relative survival of these
patients to a 5-year survival rate of over 40% [3]. Established prognostic factors for OC include
stage, histologic subtype, tumor grade and volume of residual disease after cytoreductive sur-
gery [4,5].
Three different platinum compounds, namely cisplatin, carboplatin and oxaliplatin, are cur-
rently used in the clinical practice, with numerous indications, which cover a broad spectrum
of solid tumors [6]. Their cytotoxic action is exerted through reaction with DNA and the devel-
opment of DNA damage by the formation of cross-links, Pt-d[GpG] (1,2-intrastrand cross-
links, 65%), Pt-d[ApG] (1,2-intrastrand cross-links, 25%) and in smaller extent Pt-d[GpNgG]
(1,3-intrastrand cross-links), interstrand cross-links (ICLs, the most cytotoxic) and single-nu-
cleotide damage of guanine [7]. Nucleotide excision repair (NER) is the main process by which
platinum intrastrand crosslinks and single-nucleotide damage of guanine are repaired [8,9].
On the other hand, ICL repair is complex and requires a combination of NER, Fanconi Anemia
repair pathway, translesion synthesis and homologous recombination [10–12]. Interestingly,
ICLs repair proceeds via the formation of DNA double-strand breaks (DSBs) that represent the
most lethal form of DNA damage [13]. The formation of DSBs is always followed by the phos-
phorylation of the histone H2AX, a variant of the H2A protein family, which is a component
of the histone octamer in nucleosomes. The histone H2AX is phosphorylated by kinases such
as ataxia telangiectasia mutated (ATM) and ATM-Rad3-related (ATR) in the PI3K pathway
[14]. This newly phosphorylated protein, γH2AX, is the first step in recruiting and localizing
DNA repair proteins.
The mammalian genome is protected against genotoxic insults by a network of DNA dam-
age response (DDR) pathways, which are triggered by the detection of DNA lesions through
specific sensors [15]. The subsequent step is the initiation of a signal transduction cascade,
which activates various genome-protection pathways. Since DDR is a comprehensive signaling
process that determines the cell fate either by repairing DNA damage or undergoing apoptosis,
its role has been implicated in the disease process and in the success of chemotherapy. Indeed,
it has been shown that abnormalities in the DNA repair pathways play an important role in the
malignant transformation of OC [16]. Also, expression of DNA repair proteins, such as Breast
Cancer 1 (BRCA1) and excision repair cross complementation group 1 (ERCC1) have correlat-
ed with poor survival in advanced OC and were found to be markers of resistance to platinum-
based drugs [17–19]. In addition, our previous studies focused on the levels of DNA damage in
peripheral blood mononuclear cells (PBMCs) from multiple myeloma patients have shown
that DNA damage could prospectively distinguish between patients with different degrees of
therapeutic response, providing the basis for pre-screening and selection of those patients
more likely to benefit from this treatment [20–24].
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Herein, we conducted a study to test the hypothesis that DDR, a crucial mechanism for cell
survival, is involved in resistance to platinum chemotherapy. We found that OC patients are
characterized by higher intrinsic DNA damage compared to healthy volunteers, and that the ef-
ficiency of DNA repair as measured in PBMCs from OC patients correlates with the drug sensi-
tivity of these cells and reflects the individualized response to platinum-based chemotherapy.
Materials and Methods
Patients
All patients included in this analysis were managed in a single institution (Alexandra Hospital,
Athens, Greece). Blood samples were obtained from eighteen (n = 18) patients undergoing sur-
gery for suspected ovarian cancer (mean age 62 years, range 34–77) (Table 1) prior to any ther-
apeutic treatment. Nine (n = 9) healthy individuals, age- and gender-matched to patients (all
females, mean age 60 years, range 29–73) were served as controls. All patients were staged ac-
cording to FIGO staging system. Chemotherapy was initiated within one month from surgery.
Paclitaxel at 175mg/m2 over 3 hours immediately followed by carboplatin 5–6 AUC over 60
minutes were administered every 3 weeks. Six cycles of chemotherapy were administered.
Seven patients did not receive post surgery chemotherapy: 3 had borderline tumors, 1 patient
died in the postoperative period, while 3 patients refused any treatment after surgery. Platinum
Table 1. Baseline characteristics of 18 patients with epithelial ovarian cancer included in this analysis.
Characteristic No % of total
Age (years) Median (range) 62 (34–77)
CA125 (U/ml) Median (range) 304 (105–1295)
PS 0 7 46.7
1 5 33.3
2 3 20
Histology Serous 9 50
Clear cell 6 33.3
Borderline tumors 3 16.7
Grade II 3 20
III 12 80
Chemotherapy Carboplatin/paclitaxel 11 61.1
Stage I 1 6.7
III 8 53.3
IV 6 40
Surgical procedure Ascites cytology only 1 6.7
TAH1+BSO/USO2+Omentectomy 10 66.6
Biopsy only 3 20
Pelvic exenteration 1 6.7
Residual disease 0 2 13.3
<2 cm 2 13.3
2–5 cm 3 20
>5 cm 5 33.4
Unknown 3 20
1TAH: Total Abdominal Hysterectomy
2BSO/USO: Bilateral (or Unilateral) Salpingo-Oophorectomy
doi:10.1371/journal.pone.0117654.t001
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sensitivity for the 11 patients who received first line chemotherapy was assessed according to
the Gynecologic Cancer Intergroup Committee (GCIC) criteria [25]. By these criteria, there
were 4 platinum-resistant and 7 platinum-sensitive patients. Surviving patients should have a
minimum follow-up of 2 years. All participants gave written informed consent according to
the Declaration of Helsinki Principles, and the study was approved by the Institutional Review
Board of Alexandra Hospital.
Cell treatment
The platinum-sensitive A2780 and the platinum-resistant A2780/C30 cell lines [26] were kind-
ly provided by Dr. George Koukos (Ovarian Cancer Research Center, University of Pennsylva-
nia School of Medicine, Philadelphia, Pennsylvania, USA). Cells were cultured in monolayer
by using RPMI 1640 containing 10% fetal calf serum, 100μg/ml streptomycin, 100units/ml
penicillin, 0.3mg/ml glutamine and 0.3unit/ml insulin in a 37°C incubator continuously gassed
with 5% CO2. Cells were treated with cisplatin (0–100μg/ml for 0–24h), followed by incubation
in drug-free medium for 0–24h or carboplatin (0–300μg/ml for 0–24h), followed by post-incu-
bation in drug-free medium for 0–24h.
PBMCs were isolated from freshly drawn peripheral blood using standard methods [23].
Then, cells were stimulated into proliferation using 10μg/ml phytohemagglutinin (PHA) for
48h at 37°C in RPMI 1640 supplemented with 10% FCS, 50mg/l penicillin, 50.000lU/l strepto-
mycin and subsequently treated with cisplatin (0–300μg/ml for up to 3h), followed by incuba-
tion in drug-free medium for 0–24h or carboplatin (0–1800μg/ml for up to 24h), followed by
post-incubation in drug-free medium for 0–24h.
Cytotoxicity assay
Following drug treatment, viable cells were counted by trypan blue dye-exclusion [27]. Briefly,
following incubation with the drug, cells were washed and resuspended in complete medium.
An equal volume of 0.4% trypan blue reagent was added to the cell suspension and the percent-
age of viable cells was evaluated. Assays were performed in triplicate.
Single-cell gel electrophoresis (Comet assay)
The single-cell gel electrophoresis assay was performed under alkaline conditions as described
previously [28]. Briefly, aliquots of 5x104 untreated or platinum drug treated cells were sus-
pended in low melting point agarose (1%) in PBS (135mmol/l NaCl, 2.5mmol/l KCl, pH 10) at
37°C, and spread onto fully frosted microscope slides precoated with a thin layer of 1% normal
melting agarose (Biozyme, Hameln, Germany). The cell suspension was immediately covered
with a coverglass and the slides were kept at 4°C for 1h to allow solidification of the agarose.
After removing the coverglass, cells were exposed to lysis buffer (2.5M NaCl, 100mM EDTA,
10mM Tris-HCI, pH 10, 1% Triton X-100) at 4°C for 1h. Then, the slides were placed in a hori-
zontal gel electrophoresis chamber. The chamber was filled with cold electrophoresis buffer
(1mM EDTA, 300mMNaOH, pH 13) and slides were kept at 4°C for 40min to allow the DNA
to unwind. Electrophoresis was performed for 40min (1V/cm, 255mA). After electrophoresis,
the slides were washed with neutralisation buffer (0.4M Tris-HCI, pH 7.5) for 10min and then
with H2O for 10min. All preparative steps were conducted in dark to prevent additional DNA
damage. The slides were stained with 20μl of 1μg/ml DAPI and analysed with a fluorescence
microscope (NIKON Eclipse 400) equipped with a CCD-4230A video camera. Digital images
were acquired using an image analysis system (Kinetic Analysis, Wirral, UK). Olive Tail Mo-
ments [OTM = (Tail Mean—Head Mean) x (% of DNA) / 100] of 100 cells/treatment condition
were evaluated.
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Immunofluorescence antigen staining and confocal laser scanning
microscope analysis
Aliquots of 2x104 untreated or platinum drug treated cells were adhered to coverslip coated
with 1M HCI and 50mg/ml poly-D-lysine prior to use, fixed by adding a 4% paraformaldehyde
solution for 6min at room temperature and stored at -70°C until the analysis of pATM (serine-
1981, Santa Cruz), pATR (serine-428, Cell Signaling), pChk1 (serine-345, Santa Cruz), pChk2
(threonine-68, Abcam) and γH2AX (serine-139, Cell Signaling) [29]. Cells were washed with
cold PBS and blocked with 0.5ml per well blocking buffer (0.1% Triton X-100, 0.2% skimmed
dry milk in PBS) for 1h at room temperature in a humidified box. Blocked cells were incubated
with antibodies against pATM, pATR, pChk1, pChk2 or γH2AX in blocking buffer at 4°C
overnight. After washing with blocking buffer, cells were incubated with goat anti-mouse anti-
body, FITC labeled, paired with goat anti-rabbit, TRITC labeled, for double labeling (Invitro-
gen) at a dilution of 1:4000 in blocking buffer for 1h at room temperature in the dark.
Coverslips were applied, and the edges were sealed with clear nail polish. Images were visual-
ized with a Leica TCS SP-1 confocal laser scanning microscope. Foci were manually counted
in 200 cells/treatment condition and results are expressed as the % of γH2AX positive cells
(mean±SD) from three independent experiments; positive cells are defined as cells with more
than 5 foci per cell.
Apoptosis assay
Apoptosis was evaluated by using the Cell Death Detection ELISA-PLUS kit (Roche Applied
Sciences), according to manufacturer’s instructions. In brief, cells were treated with various
doses of carboplatin (cell lines, 0–300μg/ml; PBMCs, 0–1800μg/ml) for 24h followed by incu-
bation in drug-free medium for 24h. Then, cells were collected to prepare the cytosolic frac-
tions that contained fragments of DNA. Equal volumes of these cytosolic fractions were
incubated in anti-histone antibody-coated wells (96-well plates), and the histones of the DNA
fragments were allowed to bind to the anti-histone antibodies. The peroxidase-labeled mouse
monoclonal DNA antibodies were used to localize and detect the bound fragmented DNA
using photometric detection with 2,29-azino-di-(3-ethylbenzthiazoline sulfonate) as the sub-
strate. The test quantifies apoptosis as the fold increase (expressed as Enrichment Factor, EF)
in the level of apoptosis in treated samples to untreated samples. We calculated the specific
enrichment of mono- and oligo-nucleosomes released into the cytoplasm using the following
formula: (EF) = [(absorbance of the treated cells) / (absorbance of the cells without drug treat-
ment)]. Finally, the individual apoptosis rate was expressed as the carboplatin dose sufficient to
trigger the induction of a certain Enrichment Factor (EF = 3).
Statistical analysis
The efficiency of DNA repair and the induction of apoptosis were compared between groups of
individuals using non-parametric tests. Specifically, Kruskal Wallis analysis was used for com-
parisons across all three groups, and Wilcoxon rank sum test for the pair wise comparisons.
Correlations between the values of the various DDR-related parameters within the cell lines or
PBMCs of the different OC patients were assessed by the Spearman correlation coefficient (all
groups combined). To assess the linear association between DNA damage and platinum drug
dose, apoptosis and DNA damage, as well as apoptosis and pan-nuclear staining, linear regres-
sion of these parameters was performed. A P-value less than 0.05 was considered statistically
significant. To account for multiple comparisons the Bonferonni correction was used.
DNA Damage Response in Ovarian Cancer Chemotherapy
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Results
DNA repair of platinum-induced damage in ovarian carcinoma cell lines
correlates with the drug sensitivity of these cells
To examine the molecular mechanisms implicated in the drug sensitivity of platinum chemo-
therapy, changes in key molecules of the cellular DDR pathway (pATM, pATR, pChk1, pChk2,
γH2AX) were evaluated in two ovarian carcinoma cell lines: one platinum-sensitive (A2780)
and one platinum-resistant (A2780/C30) [26]. Cells were treated with various doses of cisplatin
(0–100μg/ml) for 0–24h followed by incubation in drug-free medium for 0–24h. Both cell lines
showed a dose-dependent increase in the formation of all key molecules under study (Fig. 1A,
D). Maximal levels of these molecules were observed at 6h post-treatment, remaining stable or
slightly decreasing thereafter (Fig. 1B). Interestingly, γH2AX showed the highest induction
rates among the key molecules examined. The lowest cisplatin concentration at which γH2AX
induction could be detected was 2.5μg/ml for 1h (Fig. 1C). Moreover, cells were treated with
carboplatin (0–300μg/ml) for 0–24h followed by post-incubation in drug-free medium for
0–24h. Similar results to those obtained from the cisplatin experiments were found. That is, in
both cell lines a dose-dependent increase in the formation of all key molecules was observed
(Fig. 1E, F). Also, maximal levels of these molecules were observed at the end of the 24h treat-
ment, decreasing thereafter. Again, the γH2AX showed the highest induction rates among the
key molecules examined. Taken together, these results indicate that immunofluorescence
quantification of γH2AX foci is a powerful approach to measure DNA damage induced by
platinum drugs.
The levels of platinum-induced DNA damage in both cell lines were also evaluated using al-
kaline comet assay. This version of the comet assay detects DNA migration caused by strand
breaks, alkaline labile sites, and transient repair sites [30]. Following treatment of cells with 0–-
150μg/ml cisplatin for 3h (Fig. 2A, C) or 0–300μg/ml carboplatin for 24h (Fig. 2B, C), a linear
dose-dependent increase of DNA damage levels was obtained in both cell lines, indicating that
the method has the sensitivity and accuracy to detect and quantify platinum-induced
DNA damage.
Furthermore, using the two powerful approaches validated above, the levels of the intrinsic
DNA damage were assessed in untreated cell lines. Both immunofluorescence γH2AX staining
and alkaline comet assay showed significant differences between the two cell lines, with the in-
trinsic DNA damage being higher in A2780 than in A2780/C30 cells. Particularly, using
γH2AX immunofluorescence staining, A2780 cells exhibited 28.8±3.4% positive cells (i.e. cells
with more than 5 foci per cell) and A2780/C30 17.4±3.4% positive cells (P = 0.01; Table 2).
Moreover, by using comet assay, A2780 cells showed OTM values of 33.9±5.5 arbitrary units,
while A2780/C30 cells showed 14.4±2.9 units (P<0.001; Table 2).
To exhibit the DNA repair efficiency in these two cell lines, cells were treated with carbopla-
tin (0–300μg/ml) for 24h followed by post-incubation in drug-free medium for 0–24h and the
induced DNA damage (i.e. total DNA damage normalized by the intrinsic DNA damage) was
analyzed at the end of drug treatment. Both immunofluorescence γH2AX staining and comet
assay showed significant differences between the two cell lines. That is, in both cell lines DNA
damage reached highest levels at the end of the drug treatment, with DNA damage being signif-
icantly higher in A2780 than in A2780/C30 cells (data not shown). Thereafter, carboplatin-in-
duced DNA damage levels were reduced and the extent of repair was significantly lower in
A2780 than in A2780/C30 cells (P<0.03). Particularly, using confocal microscopy the γH2AX
foci were removed with t1/2 = 5.2±0.7h in A2780/C30 cells and 11.7±2.6h in A2780 cells. By
using comet assay, the t1/2 values for carboplatin-induced damage repair in A2780/C30 and
A2780 cells were 9.9±1.3h and 16.7±3.4h, respectively.
DNA Damage Response in Ovarian Cancer Chemotherapy
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Moreover, the Area Under the Curve (AUC) for carboplatin-induced DNA damage, a param-
eter that reflects the overall DNA damage burden resulting from initial damage formation and
DNA repair was calculated (Table 2). By using γH2AX immunofluorescence staining, A2780
cells showed AUC values [expressed as (% of γH2AX positive staining cells) x (carboplatin dose)]
of 17200±3650, and A2780/C30 cells 12400±2140 (P = 0.01). Furthermore, comet assay
Fig 1. Changes in key molecules of the DDR pathways in ovarian carcinoma cell lines. A2780/C30 cells (representative of the two OC cell lines) were
treated (A) with cisplatin (0–100μg/ml) for 3h, or (B) with 100μg/ml cisplatin, subsequently incubated in drug-free medium for various time-periods (0–24h), or
(C) with relatively small doses (0–15μg/ml) of cisplatin for up to 3h, and analyzed at the end of the treatment using confocal microscopy. Positive cells: cells
with more than 5 foci per cell. The error bars represent standard deviation. In (D) typical images showing the key molecules under study using microscope
analysis of A2780/C30 cells treated with 100μg/ml of cisplatin for 3h; upper images, immunofluorescence antigen staining; bottom images, cell nuclei labeled
with DAPI. (E) A2780/C30 cells were treated with carboplatin (0–300μg/ml) for 24h or (F) with 100μg/ml carboplatin for various time-periods (0–24h) and
analyzed using confocal microscopy. The error bars represent standard deviation. All assays were performed in triplicate.
doi:10.1371/journal.pone.0117654.g001
DNA Damage Response in Ovarian Cancer Chemotherapy
PLOS ONE | DOI:10.1371/journal.pone.0117654 February 6, 2015 7 / 19
confirmed the above findings with A2780 cells showing AUC values [expressed as (OTM x carbo-
platin dose)] of 14900±3280 while A2780/C30 cells showed AUC values of 9400±1150 (P = 0.01).
In addition, both cell types were treated with various doses of carboplatin (0–300μg/ml) for
24h and the induction of apoptosis was measured 24h post-treatment. We found that apoptosis
Fig 2. Measurement of DNA damage in ovarian carcinoma cell lines using alkaline comet assay.
A2780/C30 cells (representative of the two OC cell lines) were treated with (A) cisplatin (0–150μg/ml) for 3h
or (B) carboplatin (0–300μg/ml) for 24h, and analyzed at the end of the treatment using comet assay. The
error bars represent standard deviation. In (C) typical comet assay images of A2780/C30 cells non-treated
(NT), treated with 50μg/ml cisplatin (cis-50), 100μg/ml cisplatin (cis-100), 150μg/ml carboplatin (carbo-150) or
300μg/ml carboplatin (carbo-300). All assays were performed in triplicate.
doi:10.1371/journal.pone.0117654.g002
Table 2. DNA damage response-related parameters and associated Wilcoxon rank-sum tests in platinum-sensitive (A2780) and platinum-
resistant (A2780/C30) cell lines.
Parameter measured Method Mean(SD) P-values9
A2780 A2780/C30 A2780 vs A2780/C30
Intrinsic DNA damage γH2Ax 28.8(4.7)1 17.4(3.4) 0.01
Comet assay 33.9(5.5)2 14.4(2.9) <0.001
Induced DNA damage γH2Ax 17200(3650)3 12400(2140) 0.01
Comet assay 14900(3280)4 9400(1150) 0.01
DNA repair efﬁciency γH2Ax 11.7(2.6)5 5.2(0.7) <0.01
Comet assay 16.7(3.4)6 9.9(1.3) <0.01
Apoptosis ELISA 43.8(5.6)7 78.5(9.2) 0.001
Pan-nuclear staining γH2Ax 13400(2850)8 7500(1760) 0.001
1cells that are deﬁned as having more than 5 foci per cell, expressed as a fraction of 100
2Olive Tail Moment (OTM) values, arbitrary units
3AUC values, expressed as (% of γH2AX positive staining cells) x (carboplatin dose)
4AUC values (expressed as OTM x carboplatin dose)
5t1/2 for γH2AX foci removal, in h
6t1/2 values for carboplatin-induced damage repair, in h
7apoptosis rates expressed as doses of carboplatin inducing apoptosis (as deﬁned in the Materials and Methods section)
8AUC values, expressed as (% of pan-nuclear staining cells) x (carboplatin dose)
9Wilcoxon rank-sum tests.
doi:10.1371/journal.pone.0117654.t002
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rates were higher in the A2780 cells than in A2780/C30 cells (P = 0.001; Table 2). In particular,
A2780 cells showed evidence of apoptosis at carboplatin doses as low as 43.8±5.6μg/ml, while
A2780/C30 cells required a dose of 78.5±9.2μg/ml, indicating that the drug sensitivity of cells
inversely correlated with their DNA repair capacity (Table 2).
A noteworthy finding was that following carboplatin treatment, a fraction of cells showed
diffuse, bright pan-nuclear γH2AX staining. Previous studies have shown that pan-nuclear
γH2AX staining represents a pre-apoptotic signal associated with ATM- and JNK-dependent
apoptosis during replication [31]. In line with the results from the DNA repair efficiency exper-
iments, we observed higher levels of pan-nuclear γH2AX staining [expressed as AUC (% of
pan-nuclear staining cells) x (carboplatin dose)] in A2780 cells (13400±2850) than in A2780/
C30 cells (7500±1760) (P = 0.001, Table 2).
Deficient DNA repair of platinum-induced damage in PBMCs of OC
patients correlates with better clinical outcome
Turning to PBMCs, in agreement with previous studies [32], we found that following treatment
of non-dividing PBMCs with platinum drugs, very low or null induction rates of the key mole-
cules under study were observed. Therefore, we first treated PBMCs from nine healthy volun-
teers with various doses of PHA for up to 72h to induce proliferation of the cells. Optimal
results were obtained following 48h incubation of PBMCs with 10μg/ml PHA (data not
shown). Then, PBMCs were treated with cisplatin (0–300μg/ml for up to 3h) followed by incu-
bation in drug-free medium for 0–24h or with carboplatin (0–1800μg/ml for up to 24h) fol-
lowed by post-incubation in drug-free medium for 0–24h. In accordance to the results from
the cell lines experiments, by either of the platinum drugs, a dose-dependent induction of all
key molecules was observed (Fig. 3A, C), with the γH2AX again showing the highest induction
rates (Fig. 3B, D). Moreover, the levels of platinum-induced DNA damage in PBMCs from the
same nine healthy volunteers were measured using alkaline comet assay. We also found that
the ex vivo treatment of PBMCs with cisplatin (Fig. 3E) or carboplatin (Fig. 3F) showed a dose-
dependent increase of DNA damage levels. Taken together, the results from both cell lines and
PBMCs experiments indicate that immunofluorescence quantification of γH2AX foci and alka-
line comet assay are two powerful approaches for the quantification of platinum-induced DNA
damage in clinical samples.
Thereafter, using these assays we examined the intrinsic levels of DNA damage in untreated
PBMCs from the three groups of individuals (healthy volunteers, patients sensitive and patients
resistant to platinum chemotherapy). Both γH2AX immunofluorescence staining and comet
assay showed significant differences among the three groups of individuals (all P<0.05;
Table 3), with the intrinsic DNA damage being higher in OC patients than in healthy volun-
teers. Interestingly, in line with the results from the ovarian carcinoma cell lines experiments,
higher levels of intrinsic DNA damage were observed in PBMCs from patients sensitive com-
pared to those resistant to subsequent platinum chemotherapy (γH2AX, P = 0.05; comet assay,
P = 0.003; Table 3; Fig. 4A-D). Particularly, using γH2AX immunofluorescence staining,
platinum-sensitive patients exhibited 16.8±2.3% positive cells, platinum-resistant patients
8.9±2.4%, while healthy volunteers showed 3.9±1.2% positive cells (Table 3; Fig. 4A). By using
comet assay, patients sensitive to platinum chemotherapy showed OTM values of 20.1±5.5
arbitrary units, platinum-resistant 7.8±2.5, while healthy volunteers showed 2.4±1.1 units
(Table 3; Fig. 4C). Interestingly, to confirm that the differences in the DDR signals are really re-
flective of platinum sensitivity rather than tumor type, patients bearing the same histotype
were divided into sensitive and resistant to platinum therapy and the intrinsic DNA damage
levels were compared. Although each subgroup contains a small number of samples, the results
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showed that differences in the intrinsic DNA damage levels are reflective of platinum sensitivi-
ty. For example, in serous tumors only, using γH2AX staining, sensitive patients (n = 6)
showed higher levels of intrinsic DNA damage (mean value, 16.6% positive cells; range, 13.1–
23.2%) than resistant patient (n = 1; 7.5%). In addition, in clear cell ovarian cancer only, sensi-
tive patient (n = 1) exhibited 18.5% positive cells, while resistant patients (n = 3) only 9.4%
(range, 6.3–13.7%). Similar results were obtained using comet assay.
To examine the DNA repair efficiency in the three groups of individuals, following 48h in-
cubation of PBMCs with 10μg/ml PHA, cells were treated with carboplatin (0–1800μg/ml) for
24h, post-incubated in drug-free medium for 0–24h and the induced DNA damage was ana-
lyzed. Both γH2AX immunofluorescence staining and comet assay showed similar results.
That is, in all individuals analyzed DNA damage reached highest levels at the end of the drug
treatment, with DNA damage being higher in OC patients than in healthy volunteers; plati-
num-sensitive patients showed higher levels of DNA damage than platinum-resistant ones
(data not shown). Thereafter, DNA damage levels were eliminated and the extent of repair was
Fig 3. Changes in key molecules of the DDR pathways and comet assay in PBMCs from healthy
volunteers. PBMCs from nine healthy volunteers were ex vivo treated (A) with cisplatin (0–300μg/ml) for 3h or
(B) with 150μg/ml cisplatin, subsequently incubated in drug-free medium for various time-periods (0–24h), and
analyzed thereafter using confocal microscopy. Also, PBMCs from the same healthy volunteers were treated
(C) with carboplatin (0–1800μg/ml) for 24h or (D) with 1400μg/ml carboplatin for various times (0–24h) and
analyzed at the end of the treatment using confocal microscopy. The error bars represent standard deviation.
Finally, PBMCs were treated with (E) cisplatin (0–150μg/ml) for 3h or (F) carboplatin (0–1800μg/ml) for 24h and
analyzed thereafter using comet assay. Box plots show statistical distribution of the levels of DNA damage. The
horizontal lines within the boxes represent the median values and the vertical lines extending above and below
the box indicate maximum andminimum values, respectively. All assays were performed in triplicate.
doi:10.1371/journal.pone.0117654.g003
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higher in healthy volunteers than in patients. Interestingly, in line with the results from the cell
lines experiments, platinum-sensitive patients showed significantly lower repair efficiency
than platinum-resistant ones (P<0.03). Particularly, using confocal microscopy the γH2AX
foci were removed with t1/2 = 2.7±0.5h in healthy controls, 8.8±1.9h in platinum-resistant and
15.4±3.2h in platinum-sensitive patients. By using comet assay, the t1/2 values for carboplatin-
induced DNA damage repair were 4.8±1.4h, 12.9±1.9h and 21.4±2.6h, respectively. Notably, in
serous tumors only, the γH2AX foci were removed with t1/2 = 15.4h in sensitive patients (n = 6;
range, 12.8–18.2h) and t1/2 = 8.4h in the resistant one (n = 1). In addition, in clear cell ovarian
cancer only, sensitive patient (n = 1) showed t1/2 = 17.1h, while resistant patients t1/2 = 8.9h
(n = 3; range, 6.1–10.6h). Similar results were obtained using comet assay.
The AUC levels for carboplatin-induced DNA damage were also calculated. By using confo-
cal microscopy, platinum-sensitive patients showed AUC values of 28500±2323, platinum-re-
sistant patients 17700±1138, while healthy volunteers showed values of 10300±810 (Table 3, all
P<0.05) (Fig. 4E). Comet assay showed similar results. That is, patients sensitive to
Table 3. DNA damage response-related parameters and associated Wilcoxon rank-sum tests in PBMCs from healthy volunteers and OC
patients, sensitive or resistant to platinum therapy.
Parameter measured Method Mean (range) P-values12
HV1 (n = 9) PS2 (n = 7) PR3 (n = 4) HV vs PS HV vs PR PS vs PR
Intrinsic DNA damage γH2Ax 3.94 16.8 8.9 <0.01 0.04 0.05
2.1–6.5 13.1–23.2 6.3–13.7
Comet assay 2.45 20.1 7.8 <0.001 <0.01 0.003
1.1–5.8 16.7–31.1 3.7–16.1
Induced DNA damage γH2Ax 103006 28500 17700 0.02 0.01 0.03
7500–18700 25100–34400 13700–23500
Comet assay 98507 22700 16240 <0.01 <0.01 0.05
1050–14930 14990–29640 6840–21870
DNA repair efﬁciency γH2Ax 2.78 15.4 8.8 0.03 0.03 <0.01
1.5–3.2 12.8–18.2 6.1–10.6
Comet assay 4.89 21.4 12.9 0.02 0.01 <0.01
2.3–6.7 17.3–26.0 8.5–15.2
Apoptosis ELISA 159710 605 1020 <0.01 <0.05 <0.01
1350–2000 390–1050 800–1370
Pan-nuclear staining γH2Ax 460011 20700 11100 <0.001 <0.005 <0.01
850–9500 15900–27000 7300–19400
1HV, Healthy volunteers
2PS, Platinum-sensitive patients
3PR, Platinum-resistant patients
4PBMCs that are deﬁned as having more than 5 foci per cell, expressed as a fraction of 100
5Olive Tail Moment (OTM) values, arbitrary units
6AUC values, expressed as (% of γH2AX positive staining cells) x (carboplatin dose)
7AUC values (expressed as OTM x carboplatin dose)
8t1/2 for γH2AX foci removal, in h
9t1/2 values for carboplatin-induced damage repair, in h
10apoptosis rates expressed as doses of carboplatin inducing apoptosis (as deﬁned in the Materials and Methods section)
11AUC values, expressed as (% of pan-nuclear staining cells) x (carboplatin dose)
12Wilcoxon rank-sum tests
doi:10.1371/journal.pone.0117654.t003
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Fig 4. Intrinsic and carboplatin-induced DNA damage in PBMCs from healthy volunteers and OC patients. (A) Box plots showing statistical distribution
of the levels of the intrinsic DNA damage in untreated PBMCs using immunofluorescence quantification of γH2AX. HV, healthy volunteers; Sens: OC patients
sensitive to subsequent platinum therapy; Res: OC patients resistant to subsequent platinum therapy. (B) Typical images from confocal laser scanning
microscope analysis of PBMCs from the three groups; upper images, γH2AX staining; bottom images, cell nuclei labeled with DAPI. (C) Box plots showing
statistical distribution of the levels of the intrinsic DNA damage in untreated PBMCs using alkaline comet assay. (D) Typical comet images from untreated
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chemotherapy showed AUC values of 22700±540, platinum-resistant patients 16240±2417,
while healthy volunteers showed AUC values of 9850±540 (Table 3; Fig. 4F). Interestingly, in se-
rous tumors only, sensitive patients showed AUC values of 28400 (n = 6; range, 25100–34400),
while the platinum-resistant patient 15200 (n = 1). In addition, in clear cell ovarian cancer only,
sensitive patient (n = 1) exhibited AUC values of 29000, while resistant patients (n = 3) only
18500 (range, 13700–23500). Similar results were obtained using comet assay.
Moreover, following 48h incubation of PBMCs from the three groups of individuals with
10μg/ml PHA, cells were treated ex vivo with various doses of carboplatin (0–1800μg/ml) for
24h and the induction of apoptosis was measured 24h after the end of the treatment. In accor-
dance with the results from the cell lines experiments, we found that apoptosis rates were
higher in platinum-sensitive patients than in platinum-resistant ones, with healthy volunteers
showing the lowest rates (all P<0.05; Fig. 5A). In particular, PBMCs from platinum-sensitive
patients showed evidence of apoptosis at carboplatin doses of 605±36μg/ml, platinum-resistant
patients at 1020±158μg/ml, while healthy volunteers at 1597±254μg/ml. Interestingly, an in-
verse correlation was observed between the apoptosis rates and the DNA repair efficiencies of
the same individuals (linear regression analysis; microscope analysis: r2 = 0.94, P<0.001,
Fig. 5B; comet assay: r2 = 0.83, P<0.001, Fig. 5C). Notably, in serous tumors only, sensitive
patients (n = 6) showed evidence of apoptosis at carboplatin doses of 636μg/ml (range, 390–
1050μg/ml) and the platinum-resistant patient at 1370μg/ml (n = 1). In addition, in clear cell
ovarian cancer only, the corresponding values were 420μg/ml for the sensitive patient (n = 1)
and 877μg/ml (n = 3; range, 800–940μg/ml) for the resistant ones.
Finally, using confocal microscope analysis, in agreement with the results from the apopto-
sis experiments we observed higher levels of pan-nuclear γH2AX staining in OC patients than
in healthy volunteers (Fig. 5D, F). Particularly, patients sensitive to platinum chemotherapy
showed higher levels of pan-nuclear staining expressed as AUC (20700±3143), than platinum-
resistant patients (11100±1012; P<0.01; Table 3). Healthy volunteers showed the lowest levels
of pan-nuclear staining (4600±477).
Discussion
Mammalian cells have evolved a sophisticated signal transduction network to sense DNA dam-
age and to mount an appropriate DDR pathway. Dysregulation of the DDR pathway has been
involved into both malignant transformation and response to chemotherapy with DNA dam-
aging drugs. Therefore, we conducted a study to shed light on the DDR signaling in OC pa-
tients, sensitive or resistant to platinum chemotherapy. We found that OC patients are
characterized by higher intrinsic DNA damage compared to healthy volunteers, and that the ef-
ficiency of DNA repair as measured in PBMCs from OC patients inversely correlates with the
response of individual patients to platinum-based chemotherapy.
Platinum-based drug cytotoxicity is mainly mediated by the introduction of ICLs into the
DNA of treated cells. ICLs involve the covalent linking of the two strands of DNA which pre-
vents their separation and consequently blocks transcription, segregation and replication. Re-
pair of ICLs caused by platinum drugs involves the generation of DSBs as an intermediate step
followed by the phosphorylation of the histone H2AX [33–35]. In the present study, by using
confocal microscope analysis we first investigated changes in the expression of key molecules
PBMCs of the three groups of individuals. Box plots showing statistical distribution of the levels of DNA damage in PBMCs stimulated into proliferation using
PHA and treated with carboplatin (0–1800μg/ml) for 24h, using (E) immunofluorescence quantification of γH2AX and (F) alkaline comet assay. The horizontal
lines within the boxes represent the median values and the vertical lines extending above and below the box indicate maximum and minimum values,
respectively. All assays were performed in triplicate.
doi:10.1371/journal.pone.0117654.g004
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Fig 5. The induction of the apoptotic pathway in carboplatin-treated PBMCs. (A) Box plots showing statistical distribution of the individual apoptosis
rates, expressed as doses of carboplatin inducing apoptosis in the three groups of individuals. HV, healthy volunteers; Sens: OC patients sensitive to
subsequent platinum therapy; Res: OC patients resistant to subsequent platinum therapy. The correlations between the individual apoptosis rates and the
DNA damage in PBMCs from the same individuals using γH2AX immunofluorescence staining (B) and comet assay (C) are presented. (D) Box plots showing
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of the DDR pathways (pATM, pATR, pChk1, pChk2, γH2AX) after treatment of ovarian carci-
noma cell lines and PBMCs from healthy volunteers with platinum-based drugs. In all cell
types analyzed, a dose-dependent induction of all molecules under study was observed, with
γH2AX showing the highest induction rates. Moreover, using ovarian carcinoma cell lines and
PBMCs from healthy volunteers, we validated the comet assay, a technically simple and fast
method that detects genotoxicity in virtually any mammalian cell type [36,37]. Thereafter,
using these two powerful approaches the levels of the DNA damage were assessed in
clinical samples.
Previous reports have shown a link between ovarian carcinogenesis and the repair efficiency
of DNA damage [16]. In fact, defects in genes involved in DSBs repair, such as ERCC1, BRCA1
and BRCA2 are implicated in familial OC [17–19]. Also, a strong association between the
MGMT (O6-methylguanine-DNA methyltransferase) activity and OC risk has been described
[38]. In addition, the repair efficiency of the DNA damage induced by the alkylating agent
MNNG (N-methyl-N-nitro-N-nitrosoguanidine) decreased with progression of the cervical
cancer in a stepwise manner [39]. In the present study, we found that the intrinsic DNA dam-
age was higher in OC patients than in healthy volunteers. Moreover, in line with the findings
from the two OC cell lines, the intrinsic DNA damage was significantly higher in platinum-
sensitive than in platinum-resistant patients. High intrinsic damage could be the outcome of
increased formation of DNA damage and/or a delay in the repair of these lesions. Increased
DNA damage formation can be generated by pathological or physiological agents or processes.
These agents or processes can be exogenous such as ionizing radiation or endogenous such as
oxidative free radicals, replication across a nick, inadvertent enzyme action at fragile sites, me-
chanical shearing at anaphase bridges, metabolic byproducts, and so forth [40–42]. Physiologi-
cal processes such as V(D)J recombination, class switch recombination (CSR) and meiosis also
induce DNA damage in the genome [43–45].
Since the higher intrinsic DNA damage gives no information about the repair capacity of
the cells, we analyzed the repair efficiency of the carboplatin-induced DNA damage in both
PBMCs and OC cell lines. In agreement with the results from the intrinsic DNA damage exper-
iments, we found higher DNA repair efficiency in healthy volunteers than in OC patients, sug-
gesting that malignant transformation correlates with a reduction of DNA repair efficiency.
Whether reduced DNA repair is the cause or effect of carcinogenesis is still unclear. In any
case, since failure to repair DNA damage can lead to genomic instability, the accumulation of
DNA damage in OC patients may be involved in the pathogenesis of the disease.
Interestingly, the OC cell line sensitive to platinum treatment showed higher levels of DNA
damage than the platinum-resistant one. In line with this finding, the levels of the ex vivo plati-
num-induced DNA damage in PBMCs were higher in platinum-sensitive than in platinum-re-
sistant patients, reflecting the clinical response of OC patients to the subsequent chemotherapy
(Table 3). Moreover, in agreement with the results from the DNA repair experiments, follow-
ing treatment of the two OC cell lines with carboplatin, the apoptosis rates inversely correlated
with the repair capacity of these cells, being higher in the sensitive than in the resistant cells. In
line with this finding, following treatment of PBMCs with carboplatin, an inverse correlation
was observed between the apoptosis rates and the DNA repair efficiencies of the same individu-
als, with the apoptosis rates being significantly higher in platinum-sensitive than in platinum-
statistical distribution of the levels of the pan-nuclear immunofluorescence γH2AX staining in the three groups of individuals. The horizontal lines within the
boxes represent the median values and the vertical lines extending above and below the box indicate maximum and minimum values, respectively. (E)
Correlation between pan-nuclear γH2AX staining and the individual apoptosis rates in the same samples. (F) Typical images showing pan-nuclear
immunofluorescence γH2AX staining; upper images, γH2AX staining; bottom images, cell nuclei labeled with DAPI. All assays were performed in triplicate.
doi:10.1371/journal.pone.0117654.g005
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resistant patients and lowest in healthy volunteers (all P<0.01; Table 3). Moreover, in accor-
dance to previous studies [31,46], the correlation between apoptosis and pan-nuclear γH2AX
staining in PBMCs from the same patients confirm that pan-nuclear γH2AX staining repre-
sents a pre-apoptotic signal (linear regression analysis; r2 = 0.72, P<0.001, Fig. 5E).
It is generally accepted that ovarian cancer is not a single disease but is made up of several
different distinct histotypes. The main histotypes are epithelial in origin and include high-
grade serous carcinoma, clear cell carcinoma, endometrioid carcinoma, low-grade serous
carcinoma, and mucinous carcinoma [47]. Also, there are several rare types of non-epithelial
ovarian cancers including germ cell tumors, stromal tumors such as granulosa cell tumor and
Sertoli Leydig cell tumor [48]. On the other hand, cell lines derived from tumors are the most
frequently utilized models in in vitro drug sensitivity studies. In the present study, the cisplat-
in-sensitive A2780 cell line (the second most commonly used ovarian cancer cell line) [49],
and the cisplatin-resistant cell line A2780/C30 (derived from A2780 following continuous
exposure to increasing concentrations of cisplatin) [26] were examined. Owing to the molecu-
lar heterogeneity of the various histotypes of epithelial ovarian cancer, we recognize that a
single pair of cell lines may not accurately reflect the broad spectrum of phenotypes and that
use of patient-derived cells would enhance the study.
The results presented in the present study showed that the disease-associated nature of the
defects in DDR pathways reflected in cells of the peripheral blood of OC patients. In agreement
with these results, previous reports have shown that biomarkers (e.g. transcriptomic and epige-
netic profiles, chromosomal aberrations, telomere length, DNA damage response signals) mea-
sured in peripheral blood leukocytes (a) can distinguish between healthy controls and subjects
with a variety of diseases including various types of cancer [50–56] and (b) can predict clinical
response to therapeutic treatment [20–23,57–59]. Although one cannot rule out the possibility
that these findings may be caused by the presence in blood of circulating tumor cells [60,61],
the very small numbers of such cells make such an explanation unlikely. Therefore, it seems
possible that the regulation at the individual level of cellular responses to various influences is
partly controlled by genetically or environmentally determined systemic factors and that, as re-
gards response to the highly toxic effects of cytotoxic drugs, such systemic factors remain pre-
dominant despite any disease-related perturbations occurring in cancer cells.
Taken together, the results reported here demonstrate the critical importance of cellular re-
sponses to DNA damage in determining the cytotoxicity of platinum-based drugs, as measured
in in vitro cellular systems, as well as their therapeutic efficiency in OC patients. In particular,
we have found that the efficiency of DNA repair as measured in PBMCs from OC patients cor-
relates with the drug sensitivity of these cells and reflects the response of individual patients to
platinum-based chemotherapy. Given that these data were obtained in a readily accessible tis-
sue (PBMCs) taken prior to any therapeutic treatment, if they are confirmed in a larger study,
they may eventually be translated into novel indicators for the selection of patients who are
more likely to benefit from platinum chemotherapy.
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